<DOC>
	<DOCNO>NCT00887809</DOCNO>
	<brief_summary>The purpose study test whether experimental drug call bevacizumab give together gemcitabine docetaxel , standard chemotherapy regimen sarcoma , help sarcoma patient . This trial examine effect , good and/or bad combination gemcitabine , docetaxel bevacizumab sarcoma .</brief_summary>
	<brief_title>Gemcitabine Docetaxel With Bevacizumab Selected Sarcoma Subtypes</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirm unresectable metastatic locally recurrent leiomyosarcoma , Malignant Fibrous Histiocytoma ( MFH , also know high grade Undifferentiated Pleomorphic Sarcoma ) pleomorphic liposarcoma , rhabdomyosarcoma angiosarcoma . Zero one prior chemotherapy regimens metastatic disease . Prior adjuvant therapy count provide one year previously . Measurable disease define RECIST Adequate performance status ECOG 0 1 Patients must recover toxic effect prior chemotherapy radiation . Therapy may start least 3 week since prior cytotoxic chemotherapy , two week completion radiation therapy , one week patient tyrosine kinase inhibitor target therapy . Age 18 To 75 . As quite difficult administer high dose docetaxel gemcitabine , elderly , order protect patient safety , restrict eligibility patient age 18 75 . Adequate hematologic , hepatic renal function define Hemoglobin &gt; = 8.0 g/dl Absolute neutrophil count &gt; = 1,500/mm3 Platelet count &gt; = 100,000/mm3 Total Bilirubin &lt; = to1.5 x upper limit normal ( ULN ) . ALT ( SGOT ) AST ( SGPT ) &lt; = 5 x ULN . Alkaline Phosphatase &lt; = 2.5 x ULN ≤ 5 x ULN presence liver metastasis . Serum creatinine 2.0 mg/dL Ability understand inform consent comply treatment protocol Normal cardiac ejection fraction Urine protein : creatinine ( UPC ) ratio &lt; = 1.0 screening Uncontrolled intercurrent illness include infection congestive heart failure within 6 month . Prior therapy gemcitabine , docetaxel bevacizumab Patients receive investigational agent Patients know brain metastasis Pregnancy unwillingness use effective birth control Patients HIV disease permit , effective antiretroviral therapy , CD4 count great 400 , opportunistic infection within past 6 month . Patients anticoagulation permit stable dose warfarin lowmolecular weight heparin , major bleeds within past 6 month . Inability comply study and/or followup procedure . Life expectancy le 12 week . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study Active malignancy , superficial basal cell superficial squamous ( skin ) cell , carcinoma situ cervix within last three year Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg last &gt; 24 hour antihypertensive medication ) Any prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 Symptomatic peripheral vascular disease Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment Serious , nonhealing wound , active ulcer , nonhealing bone fracture Proteinuria screening demonstrate Urine protein : creatinine ( UPC ) ratio &gt; = 1.0 screening ( patient discover UPC ratio &gt; = 1.0 baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Known hypersensitivity component bevacizumab Pregnant ( positive pregnancy test ) lactating . Use effective mean contraception ( men woman ) subject childbearing potential History hemoptysis ( bright red blood 1/2 teaspoon per episode ) within 3 month prior study enrollment . Any history stroke transient ischemic attack within 6 month History myocardial infarction unstable angina within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Bevacizumab ( avastin )</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Taxotere ( docetaxel )</keyword>
	<keyword>09-015</keyword>
	<keyword>Soft tissue</keyword>
</DOC>